Therapeutic drug monitoring in Tuberculosis treatment: the use of alternative matrices and sampling strategies

van den Elsen, S., 2020, [Groningen]: Rijksuniversiteit Groningen. 177 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard


  • Title and contents

    Final publisher's version, 350 KB, PDF document

  • Chapter 1

    Final publisher's version, 375 KB, PDF document

  • Chapter 2

    Final publisher's version, 1 MB, PDF document

  • Chapter 3a

    Final publisher's version, 367 KB, PDF document

    Embargo ends: 26/02/2021

  • Chapter 3b

    Final publisher's version, 401 KB, PDF document

    Embargo ends: 24/01/2021

  • Chapter 3c

    Final publisher's version, 435 KB, PDF document

  • Chapter 3d

    Final publisher's version, 357 KB, PDF document

  • Chapter 4a

    Final publisher's version, 984 KB, PDF document

  • Chapter 4b

    Final publisher's version, 712 KB, PDF document

  • Chapter 5

    Final publisher's version, 548 KB, PDF document

    Embargo ends: 26/02/2021

  • Chapter 6

    Final publisher's version, 403 KB, PDF document

  • Chapter 7

    Final publisher's version, 361 KB, PDF document

  • Epilogue

    Final publisher's version, 291 KB, PDF document

  • Complete thesis

    Final publisher's version, 5 MB, PDF document

    Embargo ends: 26/02/2021

  • Propositions

    Final publisher's version, 199 KB, PDF document


Tuberculosis (TB) is the deadliest infectious disease worldwide. In 2018, approximately 1.45 million people died due to TB and an estimated 10 million individuals fell ill with TB. TB is transmitted by inhalation of small airborne droplets, containing the tubercle bacillus, produced by coughing or sneezing by individuals with contagious pulmonary TB. The treatment of TB starts with a combination of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months followed by 4 months of rifampicin and isoniazid. Nowadays, a major problem is the increase in antibiotic resistance. When the tubercle bacillus is resistant to both rifampicin and isoniazid, this is defined as multidrug-resistant TB (MDR-TB). Treatment of MDR-TB is less successful and these drugs cause more side effects than drug-susceptible TB treatment. Antibiotic resistance can be developed by insufficient drug exposure; this means the blood concentration of a drug is too low to be effective. Even using standardized dosing, drug exposure shows large inter-individual variation. Therapeutic drug monitoring (TDM) is a method to determine the optimal dose for an individual by measuring the drug concentrations in collected blood samples with dose adjustment if needed. In this thesis we investigated methods to reduce the burden of TDM for patients and medical personnel by using saliva samples instead of blood samples, by reducing the number of required blood samples, and by centralising TDM in specialised laboratories. Using these methods, we want to increase feasibility of TDM in TB endemic areas to improve treatment success rates and decrease emergence of drug resistance.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date26-Feb-2020
Place of Publication[Groningen]
Print ISBNs978-94-034-2285-5
Electronic ISBNs978-94-034-2286-2
Publication statusPublished - 2020

Download statistics

No data available

ID: 116866861